2017, the story so far: Good growth leading to increased earnings outlook for 2017
Posted by
20-Oct-2017
The first nine months of 2017 have seen steady revenue growth at UCB enabling us to increase the financial outlook for 2017 and some welcome news on our latest epilepsy product.
Revenue increased by 9% to € 3.3 billion. For our main products, revenue grew by 15% to € 2.6 billion for the first nine months of the year. This continues the trend of strong growth driven by our core medicines.
The company’s performance so far means that our financial outlook for 2017 is increased. UCB now expects 2017 revenue to reach € 4.4 - 4.5 billion; recurring EBITDA should increase to € 1.25 – 1.35 billion. Core earnings per share are expected in the range of € 4.10 – 4.50 based on an expected average of 188 million shares outstanding.
There was also some welcome news in September when our latest epilepsy medicine was approved in the US as a monotherapy for partial-onset seizures in patients 16 years of age and older.
This year has also seen another of our epilepsy products approved as monotherapy for partial-onset seizures of epilepsy patients with or without secondary generalization in Japan, and in the EU as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age.
This is positive for UCB, of course, but also good news for patients and physicians who will now have additional treatment options.
At the same time, we are progressing our promising pipeline and have reported positive results for a new psoriasis treatment. Once again, this demonstrates our commitment to making new treatment options available to people with severe diseases.
As regular readers will know, I am a keen sailor. To borrow some maritime terminology, we are enjoying a good cruise on a strong boat with a skilled crew.
For more information on this or related matters, don’t hesitate to contact me and the IR team.
Revenue increased by 9% to € 3.3 billion. For our main products, revenue grew by 15% to € 2.6 billion for the first nine months of the year. This continues the trend of strong growth driven by our core medicines.
The company’s performance so far means that our financial outlook for 2017 is increased. UCB now expects 2017 revenue to reach € 4.4 - 4.5 billion; recurring EBITDA should increase to € 1.25 – 1.35 billion. Core earnings per share are expected in the range of € 4.10 – 4.50 based on an expected average of 188 million shares outstanding.
There was also some welcome news in September when our latest epilepsy medicine was approved in the US as a monotherapy for partial-onset seizures in patients 16 years of age and older.
This year has also seen another of our epilepsy products approved as monotherapy for partial-onset seizures of epilepsy patients with or without secondary generalization in Japan, and in the EU as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age.
This is positive for UCB, of course, but also good news for patients and physicians who will now have additional treatment options.
At the same time, we are progressing our promising pipeline and have reported positive results for a new psoriasis treatment. Once again, this demonstrates our commitment to making new treatment options available to people with severe diseases.
As regular readers will know, I am a keen sailor. To borrow some maritime terminology, we are enjoying a good cruise on a strong boat with a skilled crew.
For more information on this or related matters, don’t hesitate to contact me and the IR team.
Leave a Comment